INTEREST OF CSF ABETA/TAU INDEX IN ALZHEIMER’S POSITIVE DIAGNOSIS (original) (raw)

Free PDF

Fuel-specific regional metabolic deterioration in the brain in the elderly and in early Alzheimer’s disease Cover Page

Free PDF

Current and Emerging Drug Treatment Options for Alzheimers Disease: A Systematic Review Cover Page

Free PDF

Evaluation of brain fuel metabolism during normal aging and in mild Alzheimer’s disease Cover Page

Free PDF

Quantification of cerebral glucose metabolism during normal aging: a comparison of cerebral metabolic rate and SPM analysis Cover Page

Free PDF

Safety, efficacy, and biomarker findings of PBT2 in targeting Aβ as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial Cover Page

Free PDF

Nutritional interventions and cognitive-related outcomes in patients with late-life cognitive disorders: A systematic review Cover Page

Free PDF

Clinical trial of an inhibitor of RAGE-A  interactions in Alzheimer disease Cover Page

Free PDF

Tramiprosate in mild-to-moderate Alzheimer’s disease – a randomized, double-blind, placebo-controlled, multi-centre study (the Alphase Study) Cover Page

Free PDF

Current and future treatments for Alzheimer's disease Cover Page

Effects of baseline CSF α-synuclein on regional brain atrophy rates in healthy elders, mild cognitive impairment and Alzheimer's disease

PloS one, 2013

Cerebrospinal fluid (CSF) α-synuclein is reduced in synucleinopathies, including dementia with Lewy bodies, and some studies have found increased CSF α-synuclein in Alzheimer's disease (AD). No study has explored effects of CSF α-synuclein on brain atrophy. Here we tested if baseline CSF α-synuclein affects brain atrophy rates and if these effects vary across brain regions, and across the cognitive spectrum from healthy elders (NL), to patients with mild cognitive impairment (MCI) and AD. Baseline CSF α-synuclein measurements and longitudinal structural brain magnetic resonance imaging was performed in 74 NL, 118 MCI patients and 55 AD patients. Effects of baseline CSF α-synuclein on regional atrophy rates were tested in 1) four pre-hoc defined regions possibly associated with Lewy body and/or AD pathology (amygdala, caudate, hippocampus, brainstem), and 2) all available regions of interest. Differences across diagnoses were tested by assessing the interaction of CSF α-synuclein...

Free PDF

Effects of baseline CSF α-synuclein on regional brain atrophy rates in healthy elders, mild cognitive impairment and Alzheimer's disease Cover Page